A Study of CDX-622 in Participants With Mild to Moderate Asthma (NCT07330778) | Clinical Trial Compass
RecruitingPhase 1
A Study of CDX-622 in Participants With Mild to Moderate Asthma
United States12 participantsStarted 2026-06
Plain-language summary
This is a study to determine the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of CDX-622 in adults with mild to moderate asthma.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Males and females, ≥ 18 years of age
. Diagnosis of mild to moderate asthma for at least 12 months
. Pre-bronchodilator forced expiratory volume in 1 second (FEV1) ≥ 70% of predicted normal
. Airway reversibility ≥ 12% and 200 mL improvement in FEV1
. Both males and females of child-bearing potential must agree to use contraception during the study and for 150 days after treatment
. Willing and able to comply with all study requirements and procedures
Exclusion criteria
. Females who are pregnant or nursing
. Pulmonary disease other than asthma
. Systemic diseases with elevated eosinophils other than asthma
. Hospitalization or oral corticosteroids due to asthma within the past 6 months
. History of needing ventilator support due to asthma
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Since CDX-622 is being tested in a Phase 1 trial, which primarily focuses on safety and tolerability rather than proving the treatment works, what does that mean for me in terms of what's actually known about its benefits at this stage?
2Given that this is an early-phase study measuring how safe and well-tolerated CDX-622 is, what kinds of side effects or risks are researchers watching for, and how would those be managed if I experienced them?
3My asthma is mild to moderate — before considering a Phase 1 trial, would it make more sense to try or optimize standard asthma treatments first, and what would you recommend?
4What does participation in this trial actually look like day-to-day — how many visits would I need, how long would the study last, and are there restrictions that could affect my normal routine or my current asthma medications?
5If I enroll and later decide to leave the trial, or if the study team removes me for safety reasons, what happens to my asthma care — would I be able to go back to my current treatment plan right away?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
To evaluate the safety and tolerability profile of CDX-622 in adults with mild to moderate asthma.